Lupin Partners with SteinCares to Distribute Ranibizumab for Retinal Disorders in Latin America

Pharmaceutical companies Lupin and SteinCares have entered into a license and supply agreement for the distribution of Ranibizumab in Latin America. Under the terms of the agreement, SteinCares will oversee all regulatory filings, registrations, and commercialization efforts for Ranibizumab in the region, while Lupin will manage its manufacturing.

Ranibizumab is a medication commonly used to treat retinal disorders such as age-related macular degeneration. This collaboration aims to expand access to the drug across Latin American markets. The partnership outlines clear responsibilities for both parties: SteinCares will focus on navigating regulatory processes and bringing the product to market, while Lupin will ensure consistent production of the medication.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

Date: May 26, 2025

Related posts:

Drug Patent Searching: Pharmaceutical Companies Gain 20-Year Exclusive Rights Through USPTO and EPO Database Analysis Alivus Life Sciences’ Ms. Veera to Attend Mumbai PLI Conclave 2025 on February 21 Study Links Higher Screen Time to Lower Language Scores in Children Aged 18-36 Months US Flu Season Sees Highest Pediatric Death Toll Since 2009 Swine Flu Pandemic

Author

Mark Chiang